Aida Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AIDA research report →
Companywww.aidapharma.com
Aida Pharmaceuticals, Inc. , together with its subsidiaries, engages in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. It offers antibiotics, cardiovascular, and anti-cancer drugs.
- CEO
- Biao Jin
- IPO
- 2005
- Employees
- 450
- HQ
- Hangzhou, CN
Price Chart
Valuation
- Market Cap
- $8.10K
- P/E
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 3.41
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 50.31%
- Op Margin
- 18.64%
- Net Margin
- 9.38%
- ROE
- 23.15%
- ROIC
- 8.05%
Growth & Income
- Revenue
- $29.20M · -1.48%
- Net Income
- $2.74M · 88.45%
- EPS
- $0.10 · 66.67%
- Op Income
- $5.45M
- FCF YoY
- 1652.60%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 17.62
- Avg Volume
- 974.908
Get TickerSpark's AI analysis on AIDA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AIDA Coverage
We haven't published any research on AIDA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AIDA Report →